Document is current
Any future updates will be listed below
-
Authors
Bota, Daniela A. http://orcid.org/0000-0002-9680-9060
Taylor, Thomas H.
Piccioni, David E.
Duma, Christopher M.
LaRocca, Renato V.
Kesari, Santosh
Carrillo, Jose A.
Abedi, Mehrdad
Aiken, Robert D.
Hsu, Frank P. K.
Kong, Xiao-Tang
Hsieh, Candace
Bota, Peter G.
Nistor, Gabriel I.
Keirstead, Hans S.
Dillman, Robert O.
-
Funding
Funding for this research was provided by:
Aivita Biomedical, Inc.
- License Information
-
More Information
Article History
Received: 29 September 2022
Accepted: 28 November 2022
First Online: 14 December 2022
Declarations
:
: This trial was conducted under the oversight of Institutional Review Boards at each participating institution(Scripps Health, UC San Diego Moores Cancer Center, Hoag Memorial Hospital Presbyterian, UC Irvine Medical Center, UC Davis Comprehensive Cancer Center, John Wayne Cancer Institute, Norton Cancer Institute, and Rutgers Cancer Institute). Initial consent was obtained for the collection of tumor and blood at the time of craniotomy. If eligible, a second consent was signed just prior to the initiation of concurrent RT/TMZ for ITT enrollment. Data was reviewed annually by an independent data safety committee board until all participants had completed treatment. The trial is registered at ClinicalTrials.Gov (NCT03400917).
: Consents were obtained through institutional consent forms as part of the clinical trial, and these forms are available upon request.
: Authors CH, PGB, GIN, HK, PGB and ROD are/were affiliated with Aivita Medical, the sponsor of this clinical trial.
